Zhitong App has learned that concept stocks of innovative drugs have collectively risen in the morning session. As of the time of writing, AKESO (09926) has risen by 8.21% to HKD 47.45; BEIGENE (06160) has risen by 5.7% to HKD 104.7; ALPHAMAB-B (09966) has risen by 4.92% to HKD 6.4; and Yunding Xinyao-B (01952) has risen by 4.63% to HKD 19.42.
In terms of news, according to incomplete statistics from public information, from January 1st to 7th, the domestic pharmaceutical industry has announced 9 cross-border collaborations, involving well-known multinational pharmaceutical companies such as Novartis, AstraZeneca, Bristol-Myers Squibb, Roche, and Bayer. The collaborations include various forms such as product licensing, investment, and acquisition, involving hot varieties such as small nucleic acid drugs, antibody-drug conjugates (ADC), and CAR-T therapy.
According to Guolian Securities' research report, for overseas pharmaceutical giants, ADC products have a high degree of strategic fit with their own pipeline layout. They can fill the gap in their product portfolio and save a lot of time and cost through license in, thus gaining a broad market space with lower investment. Insiders believe that 2023 will be a &#34;big year&#34; for domestic innovative drugs to go global, and 2024 is expected to be the year when sales of innovative drug products are realized.

06160

09926

159992

688235

BGNE

AKESO, BEIGENE, ALPHAMAB-B, and Yunding Xinyao-B, among other innovative pharmaceutical concept stocks, collectively rose in the morning session of the Hong Kong stock market. The domestic pharmaceutical industry has announced 9 cross-border collaborations involving well-known multinational pharmaceutical companies, including product licensing, investment, and acquisitions. Industry insiders predict that 2023 will be a "big year" for the overseas expansion of domestic innovative drugs, and 2024 is expected to be the year when sales of innovative drug products are realized.

Zhitong

BEONE MEDICINES

AKESO

Yinhua CSI Innovative Drugs Industry ETF

BeOne Medicines

Beigene

Understanding the Market | Why is the concept of innovative drugs collectively rising?